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A B S T R A C T
This study aimed to assess the effects of 8-week administration of pomegranate peel extract (PPE, ~180 mg
ellagic acid) and vitamin E (Vit E, 400 IU) alone and in combination on oxidative stress (OS) and antioxidative
capacity of hemodialysis (HD) patients. One hundred HD patients randomly divided in to 4 groups (control, PPE,
Vit E, and PPE + Vit E). The changes of malondialdehyde, oxidized low-density lipoprotein, and myeloperox-
idase in PPE+ Vit E, PPE, and Vit E groups were significantly different compared to placebo group. The Changes
of advanced oxidation protein products, superoxide dismutase, and oxygen radical absorbance capacity in
PPE + Vit E group and changes of protein carbonyls in PPE and PPE + Vit E groups were significantly different
compared to the other groups. As a result, consumption of PPE combined with Vit E was more effective than PPE
or Vit E alone to ameliorate OS and enhance antioxidative capacity of HD patients.
1. Introduction
Oxidative stress (OS) occurs when the harmony between anti-
oxidative capacity and production of oxidative agents disrupts in the
body. In this situation, the accumulation of toxic products like reactive
oxygen and nitrogen species, and other free radicals damage the cells
and biomolecules like proteins, carbohydrates, lipids, and nucleic acids
(Fallah, Sarmast, & Jafari, 2020; Jafari, 2016). Production of toxic
substances regularly occurs in the metabolic pathways, but the anti-
oxidative defense of the body confronts it. Antioxidative defense is
disrupted in some situations like chronic inflammatory conditions,
metabolic disorders, and progression of organ failure (Fallah, Sarmast,
Fatehi, & Jafari, 2020).
Chronic kidney disease (CKD), defined as impaired renal function
for more than 3 months, is one of the most serious life-threatening
diseases worldwide. More than 500 million people throughout the
world suffer from CKD (Levey & Coresh, 2012; McManus & Wynter-
Minott, 2017). The prevalence of CKD is high in Asian countries. Results
of a meta-analysis showed that the prevalence of CKD exceeds 15% in
Iranian population and even higher in women (Bouya, Balouchi,
Rafiemanesh, & Hesaraki, 2018). The prevalence of cardiovascular
diseases (CVD) and its related mortality in CKD patients is remarkable
(McManus & Wynter-Minott, 2017). Hemodialysis (HD) is a way to
compensate for renal dysfunction in these patients. Although HD im-
proves the longevity and quality of life, it does not resolve the problem
of cardiovascular events in CKD subjects. Moreover, HD may increase
the prevalence of CVD via the exacerbation of OS status and free radical
production. For this reason, physicians are looking for treatments to
enhance the antioxidative status in HD subjects (Jafari, 2016; Webster,
Nagler, Morton, & Masson, 2017).
Recently, the tendency to use natural antioxidant compounds in HD
patients has been increased. Pomegranate (Punica granatum L.) has re-
ceived much attention due to its significant amount of natural anti-
oxidants, such as polyphenols and flavonoids, and taught to have
beneficial effects on human health especially, in patients with chronic
diseases (Akhtar, Ismail, Fraternale, & Sestili, 2015; George et al., 2019;
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Liu et al., 2019). Pomegranate peels, the thin interior layer that sur-
round the pomegranate seeds, are the richest source of flavonoids and
tannins compared to the other parts of the fruit and characterized as a
powerful natural antioxidant (Ismail, Sestili, & Akhtar, 2012; Wu et al.,
2015).
Vitamin E (Vit E) composes of 8 components; 4 tocotrienols (TT)
and 4 tocopherols (TP, α, β, γ, δ), which characterized as powerful
natural antioxidants. The very weak O-H bonds in these components,
especially in tocopherols, enable them as hydrogen providers and make
them strong scavengers of free radicals and reactive oxygen species
(ROS), which protect cell membrane against lipid peroxidation (Daud
et al., 2013; Rusu, 2018). Studies have shown that the serum level of Vit
E decreases in HD patients, hence Vit E administration can be useful for
these patients (D'Arrigo, Baggetta, Tripepi, Galli, & Bolignano, 2017).
It has been demonstrated that HD causes excessive OS due the loss
of antioxidants during dialysis procedure and accumulation of oxidative
products (Liakopoulos, Roumeliotis, Gorny, Dounousi, & Mertens,
2017). Vit E is recommended to be used in the range of 400–800 IU/day
for HD patients to prevent CVD (Rusu, 2018). Results of previous stu-
dies showed that administration of Vit E alone did not effectively im-
prove OS status of HD patients, while combination of Vit E with other
antioxidants ameliorated OS in these subjects (Ahmadi, Mazooji,
Roozbeh, Mazloom, & Hasanzade, 2013; Diepeveen et al., 2005). In a
study, consumption of pomegranate juice for a long time period
ameliorated OS status in HD patients; moreover, it took at least
3 months for the beneficial antioxidative effects of pomegranate juice to
become apparent (Shema-Didi et al., 2012). Considering the restriction
of taking potassium in patients with renal failure, it seems that pome-
granate juice, which contains high potassium levels, is not suitable for
these subjects, while the use of pomegranate extracts especially po-
megranate peel extract (PPE), which contains higher levels of anti-
oxidants, can be a good alternative. Wu et al. (2015) found that ad-
ministration of pomegranate extract enhanced antioxidative capacity of
HD patients, while did not effectively improve OS status.
Combined supplementation of antioxidants may have synergistic,
indifferent, or even antagonistic effects. Referring to the scientific lit-
erature, no human clinical trial was performed on the co-supple-
mentation of Vit E and PPE. Therefore, this study aimed to assess the
effects of PPE and Vit E alone and in combination on biomarkers of
oxidative stress and antioxidative capacity of HD patients.
2. Materials and methods
2.1. Study protocol
This study was performed according to the guidelines of Helsinki
declaration and approved by Ethical Committee of Research,
Shahrekord University of Medical Sciences (IR.SKUMS.REC.1395.235).
Table 1
Baseline characteristics of participants.
Variable Intervention group P valuee
Placeboa PPEb Vit Ec PPE + Vit Ed
Age (year) 56.4 ± 16.14 57.5 ± 17.02 52.0 ± 16.9 51.2 ± 12.9 0.285
Gender (female/male) 12/12 14/11 13/11 10/14 0.933
BMI (kg/m2) 23.1 ± 3.90 23.6 ± 3.16 23.4 ± 3.17 24.6 ± 3.38 0.430
HD duration (month) 11.0 ± 6.74 9.33 ± 5.34 11.2 ± 7.44 10.8 ± 6.00 0.727
Systolic blood pressure (mmHg) 145.2 ± 17.9 147.0 ± 19.1 135.5 ± 21.0 142.7 ± 17.9 0.245
Diastolic blood pressure (mmHg) 71.1 ± 13.1 75.5 ± 15.4 83.5 ± 15.0 75.5 ± 12.6 0.121
Total cholesterol (mg/dl) 155.4 ± 33.1 165.4 ± 33.1 162.5 ± 25.4 166.5 ± 30.5 0.357
LDL (mg/dl) 98.0 ± 33.5 98.4 ± 27.8 97.4 ± 29.5 99.5 ± 45.1 0.564
Triglycerides (mg/dl) 145.3 ± 34.6 150.0 ± 32.5 140.5 ± 40.0 145.4 ± 32.0 0.255
CRP (mg/l) 18.8 ± 9.11 14.4 ± 7.60 17.2 ± 14.2 14.6 ± 6.48 0.329
Kt/vf 1.60 ± 0.10 1.50 ± 0.30 1.41 ± 0.71 1.61 ± 0.12 0.455
Note: Data are mean ± SD.
a Received 3 placebo pills.
b Received 2 pomegranate peel extract (PPE) tablets + 1 vitamin E (Vit E) placebo.
c Received 1 Vit E + 2 PPE placebo.
d Received 2 PPE tablets + 1 Vit E.
e Obtained from ANOVA.
f K shows dialyzer clearance of urea, t shows dialysis time, and V shows volume of distribution of urea.
Table 2
Dietary intakes of participants throughout the study.
Variable Intervention group P valuee
Placeboa PPEb Vit Ec PPE + Vit Ed
Energy (Kcal/day) 2125 ± 337 2205 ± 295 2157 ± 293 2175 ± 308 0.225
Carbohydrate (g/day) 325.5 ± 93.0 305.7 ± 87.6 319.7 ± 51.5 325.5 ± 71.6 0.846
Protein (g/day) 79.9 ± 16.5 85.2 ± 20.0 80.1 ± 19.5 79.2 ± 17.5 0.543
Fat (g/day) 84.2 ± 20 83.1 ± 19.7 79.8 ± 15.8 82.4 ± 16.9 0.127
PUFA (g/day) 16.3 ± 3.61 19.7 ± 7.42 15.2 ± 4.60 17.5 ± 3.72 0.625
Vitamin C (mg/day) 153.9 ± 10.2 150.1 ± 11.5 146.9 ± 10.6 147.4 ± 8.90 0.458
Vitamin E (mg/day) 5.34 ± 2.61 5.76 ± 3.44 6.01 ± 4.77 5.86 ± 3.50 0.795
Note: Data are mean ± SD, the average of 5 food recalls is represented for each food item.
a Received 3 placebo pills.
b Received 2 pomegranate peel extract (PPE) tablets + 1 vitamin E (Vit E) placebo.
c Received 1 Vit E + 2 PPE placebo.
d Received 2 PPE tablets + 1 Vit E.
e Obtained from ANOVA.
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This study was also recorded at www.irct.ir (registration ID:
IRCT20180816040814N1). Participants were fully informed of the in-
tervention protocol and they signed the written informed consent
forms.
2.2. Randomization and blinding
In this randomized, double-blinded, placebo-controlled clinical
trial, HD patients referred to HD centers in Chaharmahal-va-Bakhtiari
province of Iran were enrolled. For group allocation, stratified block
randomization procedure (Random Allocation Software) based on sex,
age, and HD duration was used. The random sequence was generated by
someone who was not involved in the intervention. The allocation was
concealed till the end of the study. Each drug (pomegranate tablet or
Vit E soft gel) and its placebo had identical shape, color, size, and
packaging; and also coded with sequential numbers by someone who
was not involved in the intervention. The interpretation of codes was
concealed to the researchers till end of the analysis. All investigators,
participants, and the laboratory technicians were blinded to the random
assignments and content of the intervention.
2.3. Medicine preparation
Pomegranate tablets (ANAR®) containing 225 mg PPE (90 mg el-
lagic acid) were purchased from Amin Pharmaceutical Company, Iran.
Vitamin E, 400 IU soft gels (dL-Alpha-Tocopheryl Acetate), were pur-
chased from Zahravi Pharmaceutical Company, Iran. The pomegranate
and vitamin E placebos were made by the same companies. Placebos
were exactly the same as the original drug in terms of shape, color, size,
and packaging.
2.4. Participants and study design
In this research, HD patients referred to HD centers in Chaharmahal-
va-Bakhtiari province of Iran were enrolled. The inclusion criteria were
as follows: patients undergoing HD for at least 3 months and 3 times a
week, without infectious diseases, sever liver disorders, malignancies,
or use drugs with definite antioxidative and antiinflammatory capacity,
or definite interaction with vitamin E and pomegranate tablets. During
the intervention, participants who did not tolerate the drugs, or altered
their dietary patterns or drugs were excluded. The selected participants
(based on inclusion criteria) were randomly divided in 4 equal parallel
groups: group Pom + Vit E, which received 2 pomegranate tablets
(450 mg PPE equal to 180 mg ellagic acid) + 1 Vit E soft gel (400 IU)
daily; group Pom, which received 2 pomegranate tablets + 1 Vit E
placebo soft gel daily; group Vit E, which received 1 Vit E soft gel + 2
pomegranate placebo tablets daily; and group placebo, which received
2 pomegranate placebo tablets + 1 Vit E placebo soft gel daily. After
one-week run-in period to prepare participants, the intervention began
and launched for 8 weeks. According to the information provided by
the pharmaceutical company for consumption of PPE tablets (ANAR®),
taking more than 2 tablets a day is not recommended for renal failure
patients. Vit E is recommended to be used in the range of 400–800 IU/
day for HD patients (Rusu, 2018). To determine the doses of PPE tablets
and Vit E, the research team held a meeting with the medical treatment
team of HD patients participating in this study. According to the
treatment protocol of the patients, maximum daily intake of 2 PPE ta-
blets and 400 mg of Vit E were allowed. A drug calendar was provided
for participants and they were asked to tick the times they took their
medicine. They were also asked to keep empty pockets of consumed
medicines and deliver them on the visits. Patients were visited 3 times a
week when they came for their HD schedule. The consumption of
medicine in days of HD schedule was after the HD procedure.
To calculate the sample size, statistical formula for parallel clinical
trials was used. Based on α= 0.05, 90% power, and standardized effect
size of malondialdehyde (MDA) as key variable (Shema-Didi et al.,Ta
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Fig. 1. CONSORT flowchart of study design.
Table 4
Comparison of changes in the study variables among the groups.
Variable Intervention group/change from baseline value P valuee
Placeboa PPEb Vit Ec PPE + Vit Ed
Ox-LDL (ng/L) 428.7 ± 840.3w −190.9 ± 590.5x −199.5 ± 612.5x −329.2 ± 645.8x <0.001
MDA (µM/L) 54.5 ± 69.7w −62.9 ± 77.6x −45.7 ± 85.1x −59.2 ± 71.8 x <0.001
AOPP (µM/L) 16.6 ± 22.1w −7.10 ± 13.2x 2.11 ± 13.9wx −22.2 ± 26.2y <0.001
PC (nM/mg protein) 0.10 ± 0.15w −0.36 ± 0.11y 0.03 ± 0.09wx −0.13 ± 0.16y <0.001
MPO (U/mg protein) 5.56 ± 10.2w −1.16 ± 5.08x −1.19 ± 5.85x −5.09 ± 5.99x <0.001
SOD (% inhibition) −1.21 ± 4.69w 0.78 ± 4.61w 1.07 ± 6.45w 3.51 ± 4.60x 0.015
FRAP (µM/L) −17.9 ± 167.2w 5.73 ± 190.2w 4.02 ± 195.6w 79.4 ± 162.0w 0.116
ORAC (µM/L) −17.9 ± 90.1w 11.9 ± 50.6w 8.54 ± 72.4w 90.5 ± 131.9x 0.001
Note: Data are mean ± SD.
Abbreviations: Ox-LDL, oxidized low-density lipoprotein; MDA, malondialdehyde; AOPP, advanced oxidation protein products; PC, protein carbonyls; MPO, mye-
loperoxidase; SOD, superoxide dismutase; FRAP, ferric reducing antioxidant power; ORAC, oxygen radical absorbance capacity.
a Received 3 placebo pills.
b Received 2 pomegranate peel extract (PPE) tablets + 1 vitamin E (Vit E) placebo.
c Received 1 Vit E + 2 PPE placebo.
d Received 2 PPE tablets + 1 Vit E.
e obtained from MANCOVA.
w,x,y The values of each marker with different superscript letters are significantly different among the groups (P < 0.05).
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2012), 17 subjects on each group were needed. To avoid losing samples
during the intervention period, 25 subjects were considered for each
group.
2.5. Dietary assessment
Dietary intakes of the patients were monitored to make sure that
they did not change their usual diet. Dietary recalls were taken at the
beginning, weeks 2, 4, 6, and at the end of the intervention period
(including a weekend) using a 24-h recall questionnaire. To calculate
energy and nutrients, Nutritionist 4 software (based on United States
Department of Agriculture (USDA) food composition table modified for
Iranian foods) was used. The average of 5-day dietary recalls was ex-
pressed as dietary intake.
2.6. Anthropometric measurements
Weight of participants, with light clothes and without shoes, was
measured before HD using a digital scale (Seca, Hamburg, Germany).
Height was measured with a stadiometer to the nearest of 0.1 cm. BMI
was calculated as weight in kg/(height in meter)2. Weight and height
were measured after overnight fasting status (Jafari et al., 2018).
2.7. Laboratory measurements
Blood samples were taken at the beginning and end of the inter-
vention prior to dialysis. The sera samples were isolated and kept at
−80 °C before analyses. Lipid peroxidation was assessed by determi-
nation of oxidized low-density lipoprotein (Ox-LDL) and mal-
ondialdehyde (MDA). A commercial ELISA kit (Eastbiopharm
Company, USA) was used to determine the levels of Ox-LDA, while
method of Morel, DiCorleto, and Chisolm (1984) was used to determine
MDA levels. Protein oxidation was assessed by determining the levels of
advanced oxidation protein products (AOPP) according to the method
of Witko-Sarsat et al. (1996) and protein carbonyls (PC) based on the
method of Levine et al. (1990). Superoxide dismutase (SOD) activity
was determined by the method of Nakayama, Akiyama, Inagaki, Gotoh,
and Oguchi (2001). Serum level of myeloperoxidase (MPO), a member
of peroxidases, was assessed by a commercial ELISA kit (Eastbiopharm
Company, USA). Total antioxidant capacity was assessed by determi-
nation of Ferric reducing antioxidant power (FRAP) according to the
method of Benzie and Strain (1996) and oxygen radical absorbance
capacity (ORAC) based on the method of Prior et al. (2003).
2.8. Statistical analyses
Quantitative data were presented as mean ± SD, and qualitative
data as number and percentage. Normality of studied variables was
assessed by Kolmogorove-Smirnov test and Q–Q plot. One-way analysis
of variance (ANOVA) was used to detect between group differences in
general characteristics, dietary intakes, and OS biomarkers at baseline.
To determine the effects of the intervention on OS biomarkers and
antioxidative defense, we used multivariate analysis of covariance
(MANCOVA). Changes from baseline values across the four groups were
compared. To adjust the probable effects of confounding factors on the
results, we considered baseline values, age, gender, baseline BMI, and
HD duration as covariates in the analyses. P-values < 0.050 were
considered statistically significant. Statistical analyses were performed
using the Statistical Package for Social Science version 20 (SPSS Inc.,
Chicago, IL, USA).
3. Results
One hundred and twenty-five medical records of HD patients who
were interested to participate in the study were evaluated and 100
patients were selected according to the inclusion criteria. They were
randomly enrolled in 4 groups. Baseline characteristics of participants
are shown in Table 1. The groups were equal in number of participants
(25 persons in each group) and there were no statistically significant
differences between them in age, gender, HD duration, and adequacy
(expressed by Kt/V index). Participants were 55 males and 45 females
with an average age of 56 years and mean HD duration of
~10.6 months (Table 1). Mean total energy and nutrient intakes did not
show significant differences among the groups (Table 2). No significant
difference was found in baseline values of Ox-LDL, MDA, AOPP, PC,
MPO, SOD, FRAP, and ORAC among the groups (Table 3, P value ob-
tained from ANOVA). Three participants were excluded from the study
(one died in the second week of intervention, one withdrew, and one
excluded due to change in treatment) and 97 participants completed the
intervention period. Fig. 1 shows the intervention process.
Table 3 shows the baseline variables and their values after an 8-
week intervention. Results of paired t-tests represented that serum level
of Ox-LDL significantly decreased in PEE + Vit E group, while sig-
nificantly increased in placebo group compared to the baseline values
(P < 0.05). In PPE and Vit E groups, serum level of Ox-LDL did not
significantly change (P > 0.05) compared to the baseline values.
Serum level of MDA significantly decreased in PPE + Vit E, Vit E, and
PPE groups, while significantly increased in the placebo group com-
pared to the baseline values (P < 0.05). Serum levels of AOPP and
MPO significantly decreased in PPE + Vit E and PPE groups, while
significantly increased in placebo group compared to the baseline va-
lues (P < 0.05). In Vit E group, serum level of AOPP and MPO did not
significantly change (P > 0.05) compared to the baseline value. Serum
level of PC significantly decreased in PPE + Vit E group, while sig-
nificantly increased in placebo group compared to the baseline values
(P < 0.05). In PPE and Vit E groups, Serum level of PC did not sig-
nificantly change (P > 0.05) compared to the baseline value. The SOD
activity and FRAP and ORAC levels significantly increased (P < 0.05)
in PPE + Vit E group, while did not significantly change (P > 0.05) in
the other groups compared to the baseline values (Table 3).
In general, results represented that after adjustments for the base-
line values, age, gender, and HD duration, our 8-week interventions
significantly reduced OS and improved antioxidative defense in HD
patients (Wilks Lambda P < 0.001). Table 4 shows the changes from
baselines values of study variables. The P values obtained from MAN-
COVA for each variable revealed significant differences among the
groups except for FRAP (Table 4). The pairwise comparisons re-
presented that changes in Ox-LDL, MDA, and MPO values of PPE + Vit
E, PPE, and Vit E groups showed significant differences compared to the
change of the placebo group. The Changes of AOPP and SOD values in
PPE + Vit E group and changes of PC value in PPE and PPE + Vit E
groups showed significant differences compared to the other groups.
The changes of FRAP value did not show significant difference among
the groups, while the change of ORAC value in PPE + Vit E group was
significantly different from the changes in the other groups (Table 4).
4. Discussion
This study showed that daily consumption of 450 mg PPE combined
with 400 IU Vit E for 8 weeks was more effective than consumption of
PPE or Vit E alone to ameliorate OS in HD patients. The combination
therapy reduced the values of lipid and protein peroxidation indices as
well as the value of MPO and increased the value of SOD. The decrease
in the value of Ox-LDL was more pronounced in the PPE + Vit E group
compared to the PPE and Vit E groups. The levels of MDA significantly
increased in the placebo group while decreased in the other groups.
The decrease in the value of MPO was also more pronounced in
patients who received PPE + Vit E compared to those who received Vit
E alone. The increase in the value of SOD was more pronounced in the
PPE + Vit E group compared to the other groups. The ORAC and FRAP
are considered as the biomarkers of total antioxidant capacity (Cao &
Prior, 1998). The values of ORAC showed significant changes between
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the 4 groups; moreover, it was significantly increased in PPE + Vit E
group. FRAP value notably increased in patients who received
PPE + Vit E compared to the baseline value. These effects might be due
to the additive or synergistic antioxidative activities of PPE and Vit E.
Patients undergoing HD therapy are exposed to developing OS
condition. The chronic and debilitating nature of the procedure and its
side effects in addition to high inflammation, malnutrition, and multi-
drug consumption impair the antioxidant defense and increase the ac-
cumulation of toxins, ROS, and other pro-oxidant components in the
body. Such conditions lead the HD patients to develop CVD (Sakaguchi
et al., 2014). Enhancement of antioxidant defense and reduction of OS
and inflammation in these patients can improve their health status.
Results of previous human clinical trials on the antioxidative effects
of Vit E supplementation in HD patients are contradictory. Some studies
represented that administration of Vit E reduced ROS synthesis, lipid
peroxidation, and platelet aggregation (Mune et al., 2018; Sohrabi,
Eftekhari, Akbarzadeh, Eskandari, & Sagheb, 2017) while some others
failed to show the antioxidative effects of Vit E in HD subjects
(Diepeveen et al., 2005; Kamgar, Zaldivar, Vaziri, & Pahl, 2009; Lu,
Erhard, Salomon, & Weiss, 2007). The function of Vit E in the body is
influenced by several factors like the amount of Vit E consumed, the
duration of consumption, and the vitamin metabolism in the body
(Daud et al., 2013). It has been recommended to use 400–800 IU/day of
Vit E for HD patients (D'Arrigo et al., 2017). There is remarkable het-
erogeneity among the studies reporting Vit E doses. Some of them used
International unit/day (IU/day) while the others used mg/day. In
general, the administered Vit E doses varied from 300 to 800 IU/day or
200 to 800 mg/day and the intervention durations launched from
1 week to 1 year. In addition, considering the malnutrition and im-
paired normal physiology of digestion, absorption, and metabolism in
HD patients, the bioavailability of Vit E in these patients is undesirable.
For these reasons, an adjunctive antioxidative treatment seems to be
necessary.
Shema-Didi et al. (2012) showed that daily consumption of 100 ml
pomegranate juice (containing 0.7 mmol polyphenols) for one year,
ameliorated OS indices i.e. MDA, AOPP, and MPO in HD patients. In
another study, pomegranate juice attenuated the exacerbation of OS
status induced by intra-venous iron administration in these patients
(Shema-Didi et al., 2013). In a cross-over study, Rivara et al. (2015)
evaluated the effects of pomegranate juice (100 ml/day for 4 weeks)
and pomegranate extract tablets (1250 mg/day for 4 weeks) in 24 HD
patients. The washout period between the 2 interventions was 4 weeks.
They reported that neither pomegranate juice nor pomegranate extract
significantly changed the OS markers as well as inflammatory markers
in these subjects. Wu et al. (2015) reported that 6-month pomegranate
extract supplementation (1000 mg/day capsule of purified pome-
granate polyphenol extract, equivalent to 600–755 mg gallic acid) had
no effects on OS markers, blood pressure, and cardiovascular risk fac-
tors in HD patients, but enhanced antioxidative capacity of the subjects.
The differences in type, amount, and the duration of the intervention as
well as the heterogeneity of pomegranate bioavailability in patients
may be the reasons of the contradiction.
Overall, results of previous clinical trials revealed that administra-
tion of Vit E (400–800 IU/day) for a short or long time period (8 weeks
to 6 months) did not effectively ameliorate OS status of HD patients
(Ahmadi et al., 2013; Diepeveen et al., 2005; Kamgar et al., 2009; Lu
et al., 2007). Considering pomegranate products, Shema-Didi et al.
(2012) found that it took at least 3 months for the antioxidative effects
of pomegranate juice consumption to appear in HD patients. In con-
trast, Wu et al. (2015) found that 6-month consumption of pomegranate
extract did not effectively ameliorate OS status of HD patients. Results
of our study showed that administration of Vit E and PPE alone did not
effectively improve biomarkers of OS and antioxidative capacity of HD
patients after an 8-week intervention, while combination therapy con-
siderably reduced OS and enhanced antioxidative capacity of the sub-
jects. This can be a valuable result and considered as the novelty of this
study because combination therapy of HD patients with Vit E and PPE
efficiently improved the mentioned biomarkers after a short period of
time, as a result of additive or synergistic effects of these compounds.
This study had limitations as follows: our patient’s conditions and their
plan of treatment did not let us to extend the intervention duration
more than 8 weeks. We also could not administer more than 400 IU/day
of vitamin E due to the patients' treatment protocol.
5. Conclusions
In general, our 8-week interventions (pomegranate tablets, Vit E soft
gel, and their combination therapy) were well tolerated in HD patients.
We concluded that combination therapy (PPE + Vit E) is more effective
than single therapy in the amelioration of OS condition and improve the
health status of HD patients. More studies with longer intervention
period of time and different doses of drugs are needed to manifest the
beneficial antioxidant therapy of the mentioned reagents. We also re-
commend studies to investigate the potential benefits of the same in-
terventions on the other type of patients with renal failure like patients
with chronic kidney disease or on earlier stages of renal failure.
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